Immunome (IMNM) Accounts Payables (2023 - 2025)
Historic Accounts Payables for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $6.1 million.
- Immunome's Accounts Payables rose 7473.0% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 7473.0%. This contributed to the annual value of $14.2 million for FY2024, which is 32854.12% up from last year.
- According to the latest figures from Q3 2025, Immunome's Accounts Payables is $6.1 million, which was up 7473.0% from $4.7 million recorded in Q2 2025.
- In the past 5 years, Immunome's Accounts Payables ranged from a high of $14.2 million in Q4 2024 and a low of $2.8 million during Q3 2023
- Its 3-year average for Accounts Payables is $5.9 million, with a median of $4.7 million in 2025.
- As far as peak fluctuations go, Immunome's Accounts Payables soared by 32854.12% in 2024, and later crashed by 3387.26% in 2025.
- Quarter analysis of 3 years shows Immunome's Accounts Payables stood at $3.3 million in 2023, then soared by 328.54% to $14.2 million in 2024, then plummeted by 56.68% to $6.1 million in 2025.
- Its Accounts Payables stands at $6.1 million for Q3 2025, versus $4.7 million for Q2 2025 and $9.1 million for Q1 2025.